All News

22 September 2008

Baxter Initiates Phase III Trial for the Treatment of Alzheimer’s DiseaseAntibodies

22 September 2008

Recruitment Completed In Ofatumumab NHL Front Line StudyAntibodies

22 September 2008

Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and TransplantationAntibodies

21 September 2008

Findings from Landmark Study show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque PsoriasisAntibodies

21 September 2008

FDA issues complete response letter to Roche for Actemra Biologics License ApplicationAntibodies

17 September 2008

InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal StudiesAntibodies

17 September 2008

Bio3 Research S.r.l. and ProtElix Inc. enter into an agreement for the development of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progressionAntibodies

16 September 2008

ENOBIA PHARMA PRESENTS PRECLINICAL DATA SHOWING ENB-0040 SIGNIFICANTLY IMPROVED SURVIVAL AND HEALED SKELETAL MANIFESTATIONS OF SEVERE HYPOPHOSPHATASIA IN MICEAntibodies

16 September 2008

New Programs Added in Antibody Collaboration Between XOMA and TakedaAntibodies

16 September 2008

New data confirms Avastin as the only biologic to demonstrate overall survival when used first-line in metastatic colorectal cancer patients with K-RAS (wild-type) gene statusAntibodies

16 September 2008

Merck KGaA: New First-Line Data Demonstrate Response Rates of Up to 80% for Erbitux in KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)Antibodies

16 September 2008

Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on AlendronateAntibodies

15 September 2008

Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008Antibodies

15 September 2008

Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One YearAntibodies

15 September 2008

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with ChemotherapyAntibodies

14 September 2008

MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI BiotechAntibodies

11 September 2008

Glenmark to initiate Phase I studies for GBR 500 by filing its IND application with the US-FDAAntibodies

11 September 2008

Merck KGaA Submits New License Application for Erbitux in Firstline Non-Small Cell Lung Cancer in EuropeAntibodies

11 September 2008

CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic MelanomaAntibodies

10 September 2008

XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical TrialsAntibodies

8 September 2008

FivePrime Initiates Phase I Clinical Trial of FP-1039 in Patients With Advanced CancersAntibodies

8 September 2008

Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate CancerAntibodies

8 September 2008

ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic IndicationsAntibodies

8 September 2008

XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing CellsAntibodies

7 September 2008

Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in OncologyAntibodies

4 September 2008

FDA: Manufacturers of TNF-Blocker Drugs Must Highlight Risk of Fungal InfectionsAntibodies

4 September 2008

Merck Serono and Ablynx Enter Into an Agreement to Co-Discover and Co-Develop Nanobodies(R)Antibodies

3 September 2008

ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck CancerAntibodies

3 September 2008

ZymoGenetics and Merck Serono Restructure PartnershipAntibodies

3 September 2008

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple MyelomaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

CD40 Agonists & CD40/L Antagonists Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CD73 Inhibitor Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Report Package: Claudin 18.2-Targeted Immunotherapeutics

PSMA-Targeted Therapy Pipeline Review